Malignant glioma progression and nitric oxide

Neurochemistry International

Volumn 49, Issue 8, 2006, Pages 764-768

  Lam Himlin, Dora ^a   Espey, Michael G ^b   Perry, George ^c,d   Smith, Mark A ^c   Castellani, Rudy J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d University of San Antonio   (United States)

Author keywords

Glioblastoma multiforme; Glioma; Nitric oxide; Nitric oxide synthase

Indexed keywords

CARMUSTINE; LOMUSTINE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ANGIOGENESIS; ARTICLE; CANCER INFILTRATION; CANCER INVASION; CANCER PATIENT; CHROMOSOME 10Q; GENE DELETION; GENE LOSS; GENE MUTATION; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; IMMUNOREACTIVITY; MOLECULAR GENETICS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BRAIN NEOPLASMS; DISEASE PROGRESSION; GLIOMA; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

EID: 33750473731     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2006.07.001     Document Type: Article

References (62)

1. Alavi J.B., and Eck S.L. Gene therapy for high grade gliomas. Expert. Opin. Biol. Ther. 1 (2001) 239-252
2. Andrade S.P., Hart I.R., and Piper P.J. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br. J. Pharmacol. 107 (1992) 1092-1095
3. Backlund L.M., Nilsson B.R., Goike H.M., Schmidt E.E., Liu L., Ichimura K., and Collins V.P. Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin. Cancer Res. 9 (2003) 4151-4158
4. Bakshi A., Nag T.C., Wadhwa S., Mahapatra A.K., and Sarkar C. The expression of nitric oxide synthases in human brain tumours and peritumoral areas. J. Neurol. Sci. 155 (1998) 196-203
5. Biernat W., Huang H., Yokoo H., Kleihues P., and Ohgaki H. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol. 14 (2004) 131-136
6. Biernat W., Kleihues P., Yonekawa Y., and Ohgaki H. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J. Neuropathol. Exp. Neurol. 56 (1997) 180-185
7. Broholm H., Rubin I., Kruse A., Braendstrup O., Schmidt K., Skriver E.B., and Lauritzen M. Nitric oxide synthase expression and enzymatic activity in human brain tumors. Clin. Neuropathol. 22 (2003) 273-281
8. Cobbs C.S., Brenman J.E., Aldape K.D., Bredt D.S., and Israel M.A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 55 (1995) 727-730
9. Colasanti M., Mollace V., Cundari E., Massoud R., Nistico G., and Lauro G.M. The generation of nitric oxide participates in gamma IFN-induced MHC class II antigen expression by cultured astrocytoma cells. Int. J. Immunopharmacol. 15 (1993) 763-771
10. Dahia P.L. PTEN, a unique tumor suppressor gene. Endocr. Relat. Cancer 7 (2000) 115-129
11. Davis F.G., Freels S., Grutsch J., Barlas S., and Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J. Neurosurg. 88 (1998) 1-10
12. Ding A.H., Nathan C.F., and Stuehr D.J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 141 (1988) 2407-2412
13. Ekstrand A.J., Sugawa N., James C.D., and Collins V.P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 4309-4313
14. Espey M.G., Miranda K.M., Feelisch M., Fukuto J., Grisham M.B., Vitek M.P., and Wink D.A. Mechanisms of cell death governed by the balance between nitrosative and oxidative stress. Ann. N. Y. Acad. Sci. 899 (2000) 209-221
15. Feinstein D.L., Galea E., Roberts S., Berquist H., Wang H., and Reis D.J. Induction of nitric oxide synthase in rat C6 glioma cells. J. Neurochem. 62 (1994) 315-321
16. Frederick L., Eley G., Wang X.Y., and James C.D. Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. Neurooncology 2 (2000) 159-163
17. Fujisawa H., Reis R.M., Nakamura M., Colella S., Yonekawa Y., Kleihues P., and Ohgaki H. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab. Invest. 80 (2000) 65-72
18. Fults D., Pedone C.A., Thompson G.E., Uchiyama C.M., Gumpper K.L., Iliev D., Vinson V.L., Tavtigian S.V., and Perry III W.L. Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme. Int. J. Oncol. 12 (1998) 905-910
19. Galea E., Feinstein D.L., and Reis D.J. Induction of calcium-independent nitric oxide synthase activity in primary rat glial cultures. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10945-10949
20. Garbossa D., Fontanella M., Pagni C.A., and Vercelli A. Nitric oxide synthase and cytochrome c oxidase changes in the tumoural and peritumoural cerebral cortex. Acta Neurochir. (Wien.) 143 (2001) 897-908
21. Huncharek M., and Kupelnick B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol. Res. 12 (2000) 107-112
22. Hurtt M.R., Moossy J., Donovan-Peluso M., and Locker J. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J. Neuropathol. Exp. Neurol. 51 (1992) 84-90
23. Ichimura K., Schmidt E.E., Miyakawa A., Goike H.M., and Collins V.P. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 22 (1998) 9-15
24. Karlbom A.E., James C.D., Boethius J., Cavenee W.K., Collins V.P., Nordenskjold M., and Larsson C. Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum. Genet. 92 (1993) 169-174
25. Khan B.V., Harrison D.G., Olbrych M.T., Alexander R.W., and Medford R.M. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 9114-9119
26. Kleihues P., Louis D.N., Scheithauer B.W., Rorke L.B., Reifenberger G., Burger P.C., and Cavenee W.K. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 61 (2002) 215-225 discussion 226-229
27. Kleihues P., and Ohgaki H. Phenotype vs. genotype in the evolution of astrocytic brain tumors. Toxicol. Pathol. 28 (2000) 164-170
28. Knobbe C.B., and Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 13 (2003) 507-518
29. Kruse C.A., Molleston M.C., Parks E.P., Schiltz P.M., Kleinschmidt-DeMasters B.K., and Hickey W.F. A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: a comparison to 9L gliosarcoma. J. Neurooncol. 22 (1994) 191-200
30. Louis D.N., Pomeroy S.L., and Cairncross J.G. Focus on central nervous system neoplasia. Cancer Cell 1 (2002) 125-128
31. Lyons C.R., Orloff G.J., and Cunningham J.M. Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line. J. Biol. Chem. 267 (1992) 6370-6374
32. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., Lu K.V., Yoshimoto K., Huang J.H., Chute D.J., Riggs B.L., Horvath S., Liau L.M., Cavenee W.K., Rao P.N., Beroukhim R., Peck T.C., Lee J.C., Sellers W.R., Stokoe D., Prados M., Cloughesy T.F., Sawyers C.L., and Mischel P.S. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353 (2005) 2012-2024
33. Murata J., Ricciardi-Castagnoli P., Dessous L'Eglise Mange P., Martin F., and Juillerat-Jeanneret L. Microglial cells induce cytotoxic effects toward colon carcinoma cells: measurement of tumor cytotoxicity with a gamma-glutamyl transpeptidase assay. Int. J. Cancer 70 (1997) 169-174
34. Nakamura M., Watanabe T., Klangby U., Asker C., Wiman K., Yonekawa Y., Kleihues P., and Ohgaki H. p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol. 11 (2001) 159-168
35. Nakamura M., Yonekawa Y., Kleihues P., and Ohgaki H. Promoter hypermethylation of the RB1 gene in glioblastomas. Lab. Invest. 81 (2001) 77-82
36. Ohgaki H., Dessen P., Jourde B., Horstmann S., Nishikawa T., Di Patre P.L., Burkhard C., Schuler D., Probst-Hensch N.M., Maiorka P.C., Baeza N., Pisani P., Yonekawa Y., Yasargil M.G., Lutolf U.M., and Kleihues P. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64 (2004) 6892-6899
37. Ohgaki H., Schauble B., zur Hausen A., von Ammon K., and Kleihues P. Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch. 427 (1995) 113-118
38. Rajkumar S.V., Buckner J.C., Schomberg P.J., Pitot H.C.T., Ingle J.N., and Cascino T.L. Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas. Neurosurgery 44 (1999) 67-73
39. Rasheed B.K., McLendon R.E., Friedman H.S., Friedman A.H., Fuchs H.E., Bigner D.D., and Bigner S.H. Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 10 (1995) 2243-2246
40. Rasheed B.K., Wiltshire R.N., Bigner S.H., and Bigner D.D. Molecular pathogenesis of malignant gliomas. Curr. Opin. Oncol. 11 (1999) 162-167
41. Reifenberger G., Liu L., Ichimura K., Schmidt E.E., and Collins V.P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53 (1993) 2736-2739
42. Rieger J., Stander M., Loschmann P.A., Heneka M., Dichgans J., Klockgether T., and Weller M. Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-beta, dexamethasone, and p53 gene transfer. Oncogene 17 (1998) 2323-2332
43. Schmidt M.C., Antweiler S., Urban N., Mueller W., Kuklik A., Meyer-Puttlitz B., Wiestler O.D., Louis D.N., Fimmers R., and von Deimling A. Impact of genotype and morphology on the prognosis of glioblastoma. J. Neuropathol Exp. Neurol. 61 (2002) 321-328
44. Schwechheimer K., Huang S., and Cavenee W.K. EGFR gene amplification-rearrangement in human glioblastomas. Int. J. Cancer 62 (1995) 145-148
45. Shinoda J., and Whittle I.R. Nitric oxide and glioma: a target for novel therapy?. Br. J. Neurosurg 15 (2001) 213-220
46. Simmons M.L., Lamborn K.R., Takahashi M., Chen P., Israel M.A., Berger M.S., Godfrey T., Nigro J., Prados M., Chang S., Barker II F.G., and Aldape K. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 61 (2001) 1122-1128
47. Simmons M.L., and Murphy S. Induction of nitric oxide synthase in glial cells. J. Neurochem. 59 (1992) 897-905
48. Smith J.S., Tachibana I., Passe S.M., Huntley B.K., Borell T.J., Iturria N., O'Fallon J.R., Schaefer P.L., Scheithauer B.W., James C.D., Buckner J.C., and Jenkins R.B. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl. Cancer Inst. 93 (2001) 1246-1256
49. Sugawa N., Ekstrand A.J., James C.D., and Collins V.P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 8602-8606
50. Swaroop G.R., Kelly P.A., Bell H.S., Shinoda J., Yamaguchi S., and Whittle I.R. The effects of chronic nitric oxide synthase suppression on glioma pathophysiology. Br. J. Neurosurg. 14 (2000) 543-548
51. Tada K., Shiraishi S., Kamiryo T., Nakamura H., Hirano H., Kuratsu J., Kochi M., Saya H., and Ushio Y. Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. J. Neurosurg. 95 (2001) 651-659
52. Terada K., Tamiya T., Daido S., Kambara H., Tanaka H., Ono Y., Matsumoto K., Ito S., Ouchida M., Ohmoto T., and Shimizu K. Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas. J. Neurooncol. 58 (2002) 107-114
53. Thomas D.D., Espey M.G., Ridnour L.A., Hofseth L.J., Mancardi D., Harris C.C., and Wink D.A. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 8894-8899
54. Tohma Y., Gratas C., Biernat W., Peraud A., Fukuda M., Yonekawa Y., Kleihues P., and Ohgaki H. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J. Neuropathol. Exp. Neurol. 57 (1998) 684-689
55. Trojan J., Johnson T.R., Rudin S.D., Ilan J., Tykocinski M.L., and Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259 (1993) 94-97
56. Watanabe K., Sato K., Biernat W., Tachibana O., von Ammon K., Ogata N., Yonekawa Y., Kleihues P., and Ohgaki H. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin. Cancer Res. 3 (1997) 523-530
57. Watanabe K., Tachibana O., Sata K., Yonekawa Y., Kleihues P., and Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6 (1996) 217-223 discussion 223-224
58. Wink D.A., and Mitchell J.B. Chemical biology of nitric oxide: insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic. Biol. Med. 25 (1998) 434-456
59. Wink D.A., Vodovotz Y., Laval J., Laval F., Dewhirst M.W., and Mitchell J.B. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19 (1998) 711-721
60. Wong A.J., Bigner S.H., Bigner D.D., Kinzler K.W., Hamilton S.R., and Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 6899-6903
61. Xie Q.W., Cho H.J., Calaycay J., Mumford R.A., Swiderek K.M., Lee T.D., Ding A., Troso T., and Nathan C. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 256 (1992) 225-228
62. Yang D.I., Yin J.H., Mishra S., Mishra R., and Hsu C.Y. NO-mediated chemoresistance in C6 glioma cells. Ann. N. Y. Acad. Sci. 962 (2002) 8-17